Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immatics NV (NQ: IMTX )

7.630 -0.170 (-2.18%)
Streaming Delayed Price Updated: 2:53 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 501,106
Open 7.800
Bid (Size) 7.630 (6)
Ask (Size) 7.660 (6)
Prev. Close 7.800
Today's Range 7.590 - 8.040
52wk Range 7.460 - 13.77
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME
From https://immatics.com/
Via GlobeNewswire

Performance

YTD
-28.82%
-28.82%
1 Month
-20.69%
-20.69%
3 Month
-33.88%
-33.88%
6 Month
-26.21%
-26.21%
1 Year
-4.98%
-4.98%

More News

Read More
Immatics Announces Pricing of $150 Million Public Offering
From https://immatics.com/
Via GlobeNewswire
Why Is Cancer-Focused Immatics Stock Trading Lower On Thursday?
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Immatics Announces Proposed $150 Million Public Offering
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024
From https://immatics.com/
Via GlobeNewswire
Biotech Stocks : Are You A Trader Or A Longer Term Investor?
Via Talk Markets
Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024
From https://immatics.com/
Via GlobeNewswire
IMTX Stock Earnings: Immatics Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Immatics Announces Second Quarter 2024 Financial Results and Business Update
From https://immatics.com/
Via GlobeNewswire
Immatics Appoints Alise Reicin to Board of Directors
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Upcoming Oral Presentation at ESMO Congress 2024
From https://immatics.com/
Via GlobeNewswire
Trading SMID Biotech Stocks In A Volatile Market
Via Talk Markets
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Immatics Announces First Quarter 2024 Financial Results and Business Update
From https://immatics.com/
Via GlobeNewswire
IMTX Stock Earnings: Immatics Beats EPS, Beats Revenue for Q4 2023
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Immatics Announces Full Year 2023 Financial Results and Corporate Update
From https://immatics.com/
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Immatics Announces Pricing of $175 Million Public Offering
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Proposed Public Offering
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Third Quarter 2023 Financial Results and Business Update
From https://immatics.com/
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.